Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 56
Filtrar
1.
Rev. méd. Maule ; 38(1): 71-76, jun. 2023. ilus
Artículo en Español | LILACS | ID: biblio-1562384

RESUMEN

The biliary pathology, is undoubtedly one of the most frequent surgical pathologies in Chile, statistical data establish the incidence of biliary pathology in over 20 years 30% of women have biliary lithiasis, of these 10% will present some complication as it is coledocolithiasis. On the other hand, hepatic fascioliasis or dystomatosis is a disease caused by hepatic fasciola, or duela, sabuaypé or Distomun hepaticum, corresponds to a flatworm, trematode of the digenea class, with affinity to stay in liver tissue, which when performing the biological cycle of the parasite can be the cause of choledocholithiasis, cholecystitis, cholangitis, pancreatitis, among others. We present a clinical case of chronic intracholedocianfasciolitis diagnosed by ERCP3,4. METHODS: Descriptive observational study, in addition to a systematic review in databases such as Pub-Med/MEDLINE, Elsevier, Cochrane and manually through the Internet in journals and public bodies. This work seeks to collect information from different authors regarding its incidence, management and established treatments. RESULTS: Inclusion and exclusion criteria were defined to analyze the characteristics of the selected articles. We present the clinical case of a 47-year-old female patient, with a history of hypertension, type 2 diabetes mellitus and egg allergy who went to the Emergency Department due to a picture characterized by epigastralgia of 3 days of evolution. During endoscopic retrograde cholangio-pancreatography (ERCP), 2 suggestive images of lyte are seen inside that finally result in 2 apparent live parasites.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Enfermedades del Conducto Colédoco/parasitología , Enfermedades del Conducto Colédoco/diagnóstico por imagen , Endosonografía/métodos , Fascioliasis/diagnóstico por imagen , Colangiopancreatografia Retrógrada Endoscópica/métodos , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Técnicas de Laboratorio Clínico , Fasciola hepatica , Fascioliasis/tratamiento farmacológico
2.
Cancer Res Treat ; 53(2): 424-435, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33171024

RESUMEN

PURPOSE: This study evaluated the efficacy of adjuvant chemotherapy (AC) in patients with resected ampulla of Vater (AoV) carcinoma. MATERIALS AND METHODS: Data from 646 patients who underwent surgical resection at Asan Medical Center between 2000 and 2017 were retrospectively reviewed. RESULTS: The median age of the patients was 62 years, and 54.2% were male. Patients were classified into AC group (n=165, 25.5%) and no AC group (n=481, 74.5%). With a median follow-up duration of 88 months, in patients with stage I, II, III, median recurrence-free survival (RFS) was not reached, 44 months, and 15 months, respectively, and the median overall survival (OS) were not reached, 88 months and 35 months, respectively. Despite no statistical significance, RFS and OS were better in stage II patients with AC than in those without AC (median RFS, 151 months vs. 38 months; p=0.156 and median OS, 153 months vs. 74 months; p=0.299). In multivariate analysis for RFS and OS, TNM stage, R1 resection status, presence of lymphovascular invasion, and perineural invasion remained significant factors, whereas AC (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.54 to 1.00; p=0.052) was marginally related with RFS. After propensity score matching in only stage II/III patients, RFS and OS with AC were numerically longer than those without AC (HR, 0.80; 95% CI, 0.60 to 1.06; p=0.116 and HR, 0.77; 95% CI, 0.56 to 1.06; p=0.111). CONCLUSION: AC with fluoropyrimidine did not improve survival of patients with resected AoV carcinoma. However, multivariate analysis with prognostic factors showed a marginally significant survival benefit with AC.


Asunto(s)
Ampolla Hepatopancreática/patología , Carcinoma/tratamiento farmacológico , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/mortalidad , Carcinoma/patología , Enfermedades del Conducto Colédoco/mortalidad , Enfermedades del Conducto Colédoco/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de Supervivencia
8.
BMJ Case Rep ; 20142014 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-25432915

RESUMEN

Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma. We describe a case of a 62-year-old woman developing jaundice with significant derangement of liver function tests on day 17 of focal radiotherapy with concomitant temozolomide. There was no structural abnormality on imaging and liver biopsy was performed. Pathology revealed absence of small terminal bile ducts affecting up to 60% of sampled portal tracts and senescence of many of the remaining small bile ducts, in keeping with a diagnosis of acute vanishing bile duct syndrome. This is a rare syndrome. It has been documented in association with Hodgkin's lymphoma and viral causes. Drugs implicated as precipitating this condition include antiseizure medications, some antibiotics, ibuprofen and antifungals. Temozolomide was stopped. The patient received supportive care, ursodeoxycholic acid 750 mg daily and cholestyramine 4 g twice daily. She was otherwise asymptomatic and her blood results returned to normal by day 129.


Asunto(s)
Antineoplásicos Alquilantes/efectos adversos , Neoplasias Encefálicas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedades del Conducto Colédoco/inducido químicamente , Dacarbazina/análogos & derivados , Glioblastoma/tratamiento farmacológico , Antineoplásicos Alquilantes/uso terapéutico , Biopsia con Aguja , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/cirugía , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Resina de Colestiramina/uso terapéutico , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Enfermedades del Conducto Colédoco/patología , Dacarbazina/efectos adversos , Dacarbazina/uso terapéutico , Femenino , Estudios de Seguimiento , Glioblastoma/diagnóstico , Glioblastoma/cirugía , Humanos , Inmunohistoquímica , Ictericia/diagnóstico , Ictericia/etiología , Pruebas de Función Hepática , Persona de Mediana Edad , Síndrome , Temozolomida , Resultado del Tratamiento , Ácido Ursodesoxicólico/uso terapéutico
9.
Eur Rev Med Pharmacol Sci ; 17(10): 1305-10, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23740441

RESUMEN

INTRODUCTION: Cholestatic liver diseases are characterized by impaired hepatocellular secretion of bile, resulting in intracellular accumulation of bile acids which result in a shift in the oxidant/prooxidant balance in favor of increased free radical activity and injury of different tissues including liver and intestine. The aim of this research was to study protective effect of lipoic acid (LA) as a potent antioxidant in cholestsis induced hepatic and intestinal injury in rats. MATERIALS AND METHODS: Forty five adult male Wistar rats were randomly assigned to four groups each containing fifteen rats as follows: sham operation (SO) (control), bile duct ligating (BDL), and BDL+LA (25 mg/kg). After fourteen days hepatic and intestinal tissue sampled and blood serum sampled for pathologic and biochemical studies. RESULTS: Levels of SOD and GPx antioxidant enzymes were higher in BDL+LA group comparing to BDL group, levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltranspeptidase (GGT), and pathologic scores in liver and intestine were lower in BDL+LA group comparing to BDL group significantly, but there is no significant difference in concentrations of total bilirubin between groups. CONCLUSIONS: Our results showed the protective potential of LA with liver and intestine damage. Despite improvements in operative technique and the development of potent, broad-spectrum antibiotics, biliary tract surgery in patients with obstructive jaundice is still associated with high morbidity and mortality rates In summary, our results show that BDL induced hepatic and intestinal injury were significantly attenuated by LA administration and the administration of LA could effectively diminish this damage.


Asunto(s)
Antioxidantes/uso terapéutico , Colestasis/tratamiento farmacológico , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Intestinos/patología , Hígado/patología , Ácido Tióctico/uso terapéutico , Animales , Colestasis/patología , Enfermedades del Conducto Colédoco/patología , Glutatión Peroxidasa/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo
10.
Int J Rheum Dis ; 16(1): 93-7, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23441778

RESUMEN

We describe a 42-year-old man who presented with painless obstructive jaundice, organomegaly and lymphadenopathy. Biopsy of the ampulla of Vater revealed the presence of increased populations of plasma cells which stained positively for immunoglobulin G4. He was treated with prednisolone and demonstrated significant clinical improvement 1 month later. A further case is described and a review of the literature is also provided.


Asunto(s)
Enfermedades Autoinmunes/diagnóstico , Enfermedades del Conducto Colédoco/patología , Hipergammaglobulinemia/diagnóstico , Inmunoglobulina G/sangre , Trastornos Linfoproliferativos/diagnóstico , Esclerosis/diagnóstico , Adulto , Ampolla Hepatopancreática/metabolismo , Ampolla Hepatopancreática/patología , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Enfermedades del Conducto Colédoco/inmunología , Diagnóstico Diferencial , Glucocorticoides/uso terapéutico , Humanos , Hipergammaglobulinemia/tratamiento farmacológico , Hipergammaglobulinemia/inmunología , Ictericia Obstructiva/diagnóstico , Ictericia Obstructiva/tratamiento farmacológico , Ictericia Obstructiva/inmunología , Enfermedades Linfáticas/diagnóstico , Enfermedades Linfáticas/tratamiento farmacológico , Enfermedades Linfáticas/inmunología , Trastornos Linfoproliferativos/tratamiento farmacológico , Trastornos Linfoproliferativos/inmunología , Masculino , Células Plasmáticas/metabolismo , Células Plasmáticas/patología , Prednisolona/uso terapéutico , Esclerosis/tratamiento farmacológico , Esclerosis/inmunología , Resultado del Tratamiento
15.
Intern Med ; 48(12): 945-52, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19525579

RESUMEN

OBJECTIVE: To evaluate the effects of localized irrigation with epinephrine saline after endoscopic retrograde cholangiopancreatography (ERCP). PATIENTS AND METHODS: One hundred and fourteen patients who underwent ERCP in our institute were treated with or without irrigation using epinephrine diluted in saline after ERCP to prevent post-ERCP pancreatitis. The serum amylase levels, white blood cell counts, and urine amylase levels were measured at 24 and 48 hours after ERCP. RESULTS: The treatment resulted in improvements in all items. A univariate analysis of the explanatory variables between the treatment and untreated groups revealed the treatment to be effective, but not statistically significant. Gender and cannulation of the pancreatic duct were the only variables with significant partial regression coefficients in the multiple regression model with all explanatory variables (p=0.045). When a stratified analysis was conducted using gender as a moderator variable, the treatment became a significant preventive factor (p=0.038), and cannulation of the pancreatic duct was a significant risk factor (p=0.027) in female patients. CONCLUSION: We suggest that irrigating with epinephrine saline into the papilla may be effective for preventing pancreatitis in female patients who received ERCP with cannulation of their pancreatic duct.


Asunto(s)
Agonistas Adrenérgicos/uso terapéutico , Ampolla Hepatopancreática/patología , Amilasas/sangre , Colangiopancreatografia Retrógrada Endoscópica , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Edema/tratamiento farmacológico , Epinefrina/uso terapéutico , Agonistas Adrenérgicos/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Enfermedades del Conducto Colédoco/sangre , Enfermedades del Conducto Colédoco/patología , Edema/sangre , Edema/patología , Epinefrina/administración & dosificación , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pancreatitis/prevención & control , Análisis de Regresión , Estudios Retrospectivos , Irrigación Terapéutica , Resultado del Tratamiento
18.
Gastrointest Endosc ; 69(6): 1111-6, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19243765

RESUMEN

BACKGROUND: The therapeutic approach in patients with sphincter of Oddi (SO) dysfunction (SOD) aims to reduce the resistance to the flow of bile or pancreatic juice. Vardenafil inhibits the activity of phosphodiesterase type 5 (PDE-5), which degrades cyclic guanossine monophosphate (cGMP) and results in relaxation of smooth muscle. OBJECTIVE: The present study was performed to determine the effects of vardenafil on SO motility in patients with suspected SOD. DESIGN: Prospective study. SETTINGS: Single university center. PATIENTS AND INTERVENTIONS: Twenty consecutive adult patients with suspected SOD were scheduled to undergo ERCP and SO manometry by standard methods. A second recording was performed in the same position 20 minutes after administration of 10 mg vardenafil dissolved in 10 mL saline solution into the duodenum through a conventional catheter. SO pressures and motor function were compared in all patients with suspected SOD before and after administration of vardenafil. RESULTS: After administration of 10 mg of vardenafil, the mean basal sphincter pressure was reduced from 59.5 to 26.9 mm Hg (P < .001), and the mean phasic amplitude was reduced from 132.2 to 66.2 mm Hg (P < .001). The mean phasic wave frequency was not changed after administration of vardenafil (7.2/min vs 6.6/min, respectively, P = .07). These results did not differ between SOD types. No significant difference in manometric data were detected before and after administration of vardenafil between cholecystectomy and gallbladder in situ groups. Transient headache was observed in 1 patient, and the procedure-related complication was post-ERCP pancreatitis (n = 2 [10%]). LIMITATIONS: The small sample size and uncontrolled study. CONCLUSION: Vardenafil inhibits SO motility in patients with suspected SOD and reduces basal SO pressure, without significant adverse effects.


Asunto(s)
Enfermedades del Conducto Colédoco/tratamiento farmacológico , Imidazoles/uso terapéutico , Inhibidores de Fosfodiesterasa 5 , Inhibidores de Fosfodiesterasa/uso terapéutico , Piperazinas/uso terapéutico , Esfínter de la Ampolla Hepatopancreática/efectos de los fármacos , Vasodilatadores/uso terapéutico , Administración Tópica , Adulto , Anciano , Colangiopancreatografia Retrógrada Endoscópica , Constricción Patológica/tratamiento farmacológico , Femenino , Humanos , Imidazoles/efectos adversos , Masculino , Manometría , Persona de Mediana Edad , Inhibidores de Fosfodiesterasa/efectos adversos , Piperazinas/efectos adversos , Síndrome Poscolecistectomía/tratamiento farmacológico , Estudios Prospectivos , Esfinterotomía Endoscópica , Sulfonas/efectos adversos , Sulfonas/uso terapéutico , Triazinas/efectos adversos , Triazinas/uso terapéutico , Diclorhidrato de Vardenafil , Vasodilatadores/efectos adversos
20.
Pancreas ; 35(4): e51-60, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18090232

RESUMEN

OBJECTIVES: To evaluate the clinical significance of a swollen main duodenal papilla and the associated immunohistopathologic findings in patients with autoimmune pancreatitis (AIP). METHODS: Seventeen consecutive patients with AIP registered between April 2001 and October 2005 who underwent both endoscopic retrograde cholangiopancreatography and endoscopic biopsy were enrolled in this study. The endoscopic features, stromal inflammatory cell infiltrate (SICI), and results of immunohistochemical examination of the duodenal papilla using IgG4, CD3, and CD79a antibodies were retrospectively reviewed. These findings in the AIP patients were compared with those in 12 patients with chronic alcoholic tumor-forming pancreatitis (CAP). The numbers of cells in the SICI and of IgG4-positive plasma cells per high-power field were counted in all the histopathologic specimens. RESULTS: A swollen main duodenal papilla was observed in 11 (11 [64.7%]/17) patients with AIP and 4 (4 [33.3%]/12) patients with CAP (P < 0.05). Resolution of the swollen main duodenal papilla was observed in all of these 11 patients with AIP (11 [100%]/11) in response to treatment with corticosteroids. On the other hand, the 6 patients without elevated serum IgG4 or a swollen duodenal papilla, but with a swollen pancreas, improved even without corticosteroid treatment. The number of cells in the SICI in the AIP patients was significantly higher than that in the CAP patients. Although in 13 of 17 AIP patients, infiltration by IgG4-positive plasma cells was detected in the duodenal papilla, no such significant infiltration of the duodenal papilla by IgG4-positive plasma cells was observed in the patients with CAP (P < 0.05). More predominant T-cell infiltration of the duodenal papilla was recognized in the AIP patients than in the CAP patients (P < 0.05). CONCLUSIONS: These results suggest that a swollen main duodenal papilla with IgG4-positive plasma cell and T-cell-dominant infiltration and an abundant stromal cell infiltrate are characteristic findings in AIP. We suggest that these findings may be valuable adjuncts to the diagnosis of AIP as well as for selecting suitable candidates for corticosteroid therapy.


Asunto(s)
Ampolla Hepatopancreática/patología , Enfermedades Autoinmunes/patología , Enfermedades del Conducto Colédoco/patología , Pancreatitis Alcohólica/patología , Pancreatitis Crónica/patología , Pancreatitis/patología , Corticoesteroides/uso terapéutico , Anciano , Ampolla Hepatopancreática/inmunología , Antiinflamatorios/uso terapéutico , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Complejo CD3/análisis , Antígenos CD79/análisis , Colangiopancreatografia Retrógrada Endoscópica , Enfermedades del Conducto Colédoco/tratamiento farmacológico , Enfermedades del Conducto Colédoco/inmunología , Femenino , Humanos , Inmunoglobulina G/análisis , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Pancreatitis/tratamiento farmacológico , Pancreatitis/inmunología , Pancreatitis Alcohólica/tratamiento farmacológico , Pancreatitis Alcohólica/inmunología , Pancreatitis Crónica/tratamiento farmacológico , Pancreatitis Crónica/inmunología , Selección de Paciente , Células Plasmáticas/patología , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Células del Estroma/patología , Linfocitos T/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA